LAURUS Labs
Chemistry for Better Living

September 18, 2026

To	To
The Corporate Relations Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Code: 540222**	**The Listing Department** **National Stock Exchange of India Ltd.,** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Code: LAURUSLABS**

Subject: Investor Presentation

Dear Sir / Madam,

Please find enclosed investor presentation and the same is also being uploaded on the website of the Company i.e., www.lauruslabs.com.

We request you to please take the same on record.

Thanking You,

Yours faithfully,
For **Laurus Labs Limited**
VENKATESWAR REDDY GOGIREDDY
Digitally signed by VENKATESWAR REDDY GOGIREDDY
Date: 2026.09.18 18:09:24 +05'30'
G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Investor Presentation

September 2026

Safe Harbor Statement

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same.

Strong execution, Leading Platform & Investing for long term growth

Strong Operational performance track record

Revenue FY26
₹6,813 Cr ▲ 23%
CAGR FY20-26 ▲16%

EBITDA FY26
₹1,826 Cr
▲ 64%

EBITDA Margin FY26
26.8%
Guiding **>30%** from FY27+

Employees **8,470**

Net debt / EBITDA **1.3x**

Leading Manufacturing and Technology platform

Small molecule
Flow chemistry
Bio catalysis
Cell & Gene
ADC
Peptide
High potency
Continuous DP
Spray drying

Scientist **1,570+**

Integrated solution API to Formulations at Scale with global regulatory approvals

15 Manufacturing sites
6 R&D center

1425+ Quality audits & Inspections
0 Critical findings

Accelerated CAPEX to meet growing Demand, Scale and Future growth



85% Growth Capex

Multiple large Growth projects (API + Peptides + FDF + Fermentation + CGT + ADC)

20 years of deep commitment with Customer & Integrated solution as top priority

VISION

To become Leading player offering Integrated solutions in creating a healthier world

Strategic Framework driving Business execution

Scale
Large scale manufacturing sites (fungible) ensuring Agility in responding to changing customer needs of Scale

Integrated Service
Research-driven operational excellence to deliver Value & transform along the chemistry value chain

Quality & Compliance
Stringent global benchmarks with approach to deliver One Quality standard product for all markets

Innovation & Automation
Cutting edge technology platforms to solve customer challenges and achieve their sustainability goals

Sustainability
Deliver long term Profitable growth and at the same time create value for Society and Environment

Talent
Cultivate high performing Talent base and promote leadership culture to secure order delivery capability

Unparalleled experience on Multi-site manufacturing capability
Proven track record in quality, regulatory and compliance

United by Core Values

Knowledge | Innovation | Excellence | Care | Integrity

Integrated CDMO & CMO platform, delivering Customer value through 2 Core business divisions

1

CDMO

Pre-Clinical → Clinical supplies (Phase I, II and III) → Commercial supplies → Lifecycle management

Small Molecules
(Drug Substance & Drug Product)

- Development & manufacturing services (RSM, Intermediates, API, Drug product service)
- Complex chemistry (High potent, Bio-catalysis, Flow Chemistry, SDD), Regulatory services

Specialized Modalities

- Gene technology development & manufacturing
- Peptides
- Anti Body Drug Conjugates (ADC)
- Precision fermentation

Animal Health and Crop Protection

- Custom development & manufacturing of ingredients, Finished formulations
- Regulatory services

2

AFFORDABLE MEDICINES

- Integrated capabilities across API and Formulation Development & manufacturing services, CMO supplies
- Therapy focus: ARV, Oncology, Cardio, Diabetic, Gastro, CNS, Asthma and Ophthalmic

Strengthening Development & Manufacturing Capabilities to meet Customer demand

Small Molecules API & FDF

- Unit 1 & 3, Vizag **+3600 kL**
- Unit 5, Vizag **161 kL**
- ● Unit 7, Vizag *(new site)*
- ● Unit 2, Vizag **+12bn units**
- ● Unit 4, Vizag **+2430 kL**
- Unit 6, Vizag **1476 kL**
- ● Unit 10, Vizag *(new site)*
- ● LSPL 2, Vizag **+500 kL**
- LSPL 4, Vizag **+300 kL**
- ● KRKA JV site, Hyderabad *(new site)*

R & D

- R&D 1 & Kilo lab, Hyderabad
- R&D 2, Hyderabad

Fermentation

- LB-1 & LB-2, Bangalore **+240 kL**
- ● LB-4, Vizag **+400 kL** *(new site)*

CGT & ADC

- CAR-T unit-1, Mumbai **+600 treatment**
- CAR-T unit-2, Mumbai **+2500 treatment**
- ● Gene Therapy/ADC, Hyderabad

6 Research & Development assets

15 Manufacturing assets

8800 kL	12 billion	240 kL	1570	56000 m^2
API capacity	FDF capacity	Fermentation capacity	Research Scientists	GLP lab facility

● Site under expansion or construction

Multiple Sites - One Quality Standard

U.S. FOOD & DRUG ADMINISTRATION · World Health Organization · EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH · ANVISA · Pmda JAPAN · MHRA Regulating Medicines and Medical Devices · Australian Government Department of Health Therapeutic Goods Administration · JAZMP

Acceleration in Growth CAPEX projects across portfolio and technologies

> ₹ 3,000 Cr Cumulative CAPEX over FY27 and FY28. Q1 CAPEX reached 19% of Revenue

>85% Growth CAPEX

Key projects in API, Formulations, Peptides, Fermentation, Gene Therapy and Antibody Drug Conjugates

Healthy order book, internal pipeline and key Customers

ATR improving in medium-term in-line with 6 year Long term average

1QFY27 CAPEX : ₹394 Cr

(19% of Revenue)



FY22-26 CAPEX : ₹4300 Cr

(15% of Revenue)



Asset turnover progress (ATR)



From FY22 to FY26, Laurus invested ₹ 4300 Cr building diversified portfolio across technologies and We are further strengthening our Manufacturing network, based on Customer needs

Selected CAPEX projects highlights – Enhancing broadest capability offering

Unit 7
Large-scale API facility

- Multiple API blocks, Flexible manufacturing
- Large-scale API capacity
- Future expansion
- Phase 1 starts in 2027

Commercial Gene & ADC platform with fill-finish

- One-stop Service platform for complete ADC programs (Payload-linker, Conjugation, Fill-finish)
- Commercial-scale capacity
- Qualification by mid-2027

Enzyme Fermentation plant boosting biocatalysis capacity

- Commercial scale manufacturing and Future expansion scope
- Precision fermentation and strain engineering
- On-line by 2026 end

Confirming SBTi targets and consistent ESG recognition

SBTi roadmap towards GHG reduction target 2031

Scope 1 + 2



Absolute reduction by 42% until FY31 (vs. FY25)

Scope 3



Intensity reduction per ₹ by 51.6% until FY31 (vs. FY25)

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

- >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites
- Near term GHG reduction target validated by SBTi
- Sustainable Procurement code inline with ISO 20400:2017 principles established

Key recognitions for our ESG programs

SILVER | Top 15% ecovadis Sustainability Rating JUN 2026

Laurus Labs Limited Pharmaceuticals
Sustainability Yearbook Member
Corporate Sustainability Assessment (CSA) 2025

MSCI ESG RATINGS BBB
CCC | B | BB | BBB | A | AA | AAA

S&P Global ESG Score
81/100
Data Availability: Very High
Last updated: November 05, 2025

NATIONAL SAFETY COUNCIL OF INDIA SAFETY AWARDS

UN GLOBAL COMPACT

Great Place To Work. Certified JUL 2025-JUL 2026 INDIA

LAURUS Labs Chemistry for Better Living

Laurus operates in leading technology platform in a Fast growing CDMO market

CDMO small molecule market

Global size # & Growth (2025-34)

~ **$ 85 bn** **>7% CAGR ***	- Leading pipeline modality - Rising complexity - Integrated supplies

Indian market size & Growth (2025-34)

~ **$ 2 bn** **>14% CAGR ***	- Service capability advancement (complex APIs) - Reliability - Increased outsourcing

Laurus

Key Technology platform	**Integrated D & M solution**
Small molecule	Preclinical/Phase 1
Fermentation/Bio-catalysis	Phase 2
Drug Product Service	Phase 3
Peptides	Commercial (DS/DP)
Hi-Potent (OEB 4/5)	Life cycle management
Anti-body Drug Conjugates	**>1,570** Scientists
Cell & Gene + +	

* Industry, Expected annual growth rate, # including Peptides

LAURUS Labs
Chemistry for Better Living

Business Division: Strong diversified growth, underpin by integrated model

Strong diversified performance

Divisions	CAGR % FY 20-26	FY 26 Growth	FY26 Revenue mix
CDMO [1]	+33%	+36%	31%
Affordable medicines (GENERICS) [2]	+12%	+18%	69%

ARV de-risking continues

Transformation continues with consistent rise in CDMO revenue share and continued decline in ARV share



[1] includes Small Molecules & Bio business performance, [2] includes FDF and API business performance, * Oncology, Cardiovascular, Diabetes, Gastro and Asthma

LAURUS Labs
Chemistry for Better Living

CDMO – Small molecule: Recognized Industry Player, Continuous capacity expansion

Revenue Growth



> 125* Strong Pipeline, well diversified across technology, indications and customer type

* Based on data as on March 2026

Priorities

- Demand led capacity creation & Invest in enviable technologies
- Commercial execution of pipeline opportunities
- End-to-end execution excellence (Integrated projects)

Recent Highlights

- Strong visibility on late-stage projects & commercial API supplies
- Large scale Peptides manufacturing facility build on track
- Expanding Pipeline, based on trust, capabilities, scale and delivery
- Deepening client engagement on complex modalities and fully integrated projects (Pre-clinical to Drug product service)
- Continuing CAPEX in large-scale API & fermentation capacity

LAURUS Labs
Chemistry for Better Living

BIO – Delivering Full service Precision Fermentation technology

Revenue Growth



Priorities

- Accelerate Enzymatic and bio-catalysis application
- Increase product development throughput
- Commercial scale Capacity creation

Recent Highlights

- Diversified growth & pipeline progress on larger Global accounts
- Improving product mix and customers mix within CDMO and AOF
- Traction in the enzymatic technology application across small molecule clinical and commercial API projects
- Large-scale Fermentation manufacturing site (Vizag) build up on track – commissioning expected by Dec 2026

LAURUS Labs
Chemistry for Better Living

Affordable Medicines – Integrated approach, Portfolio expansion to drive growth

Revenue Growth



Priorities

- Creation and allocation of Capacities, Cost efficiency
- Long term CMO tie-ups, New launches, Integrated supplies

Recent Highlights

- Heathy market dynamics across portfolio supporting orderbook. Maintain ARV global leadership
- Consistent deliveries track record amidst supply chain challenges
- Ongoing capacity creation/allocation, new launch ramp-up/integrated CMO and expanding footprint across DM/EM
- KRKA JV FDF site progress fully on track. Phase-I to be opened in mid-2027 focusing on High Potent and General OSD capability
- Portfolio of 92 DMFs and 96 Dossiers filed across US/EU/Canada

LAURUS Labs
Chemistry for Better Living

Advanced Biologics – Gene / ADC platform building continues

Gene Therapy & Anti body Drug Conjugates (ADC)

- In-licensed two ADC assets from Aarvik Therapeutics for development and commercialization for India markets
- PD team more than doubled in last 6 months & continue to grow
- Manufacturing facility build up on track with focus on Integrated offering (PD, bioconjugation and finished ADCs capabilities)
- Gram to Multi-Kg scale to support clinical & commercial supplies


Facility under construction – Qualification expected by end 2027

Cell Therapy

- Continued uptake in volumes >660 infusions as on Jun 2026
- 2nd GMP production facility in Navi Mumbai operationalized in March 2026, with capacity to produce +2,500 treatment
- BCMA Ph-1 trails ongoing for r/r Multiple Myeloma
- Cipla partnership for South Africa market progressing well


ImmunoACT presenting CAR-T cell therapy platform at Bharat Innovates 2026, France

Strategic priorities

- Accelerate NexCar19 clinical adoption
- Portfolio expansion
- Global partnerships & Licensing opportunities

LAURUS Labs
Chemistry for Better Living

Healthy OCF and Accelerating CAPEX to drive future growth

Operating Cash flows and CAPEX investments



Leverage profile



LAURUS Labs
Chemistry for Better Living

Financial Highlights FY 2020-26

Revenue



EBITDA & Gross Profit Margins



RoCE



Net Profit



LAURUS Labs
Chemistry for Better Living

Appendix

LAURUS Labs
Chemistry for Better Living

1Q FY27: Executive Summary

- Continued strong Q1 performance ; ₹ 2,026 Cr Revenue with 29% growth
- Strong growth in CDMO revenue driven by commercial projects supplies and steady momentum in Affordable Medicines segment
- ₹ 644 Cr EBITDA with margins of 31.8%, increased by 7.0% pts, contributed by enhanced CDMO revenue and operational leverage
- Gross margins expansion of over 3.3% pts to 62.7% on healthy business segment mix
- Continued investment into manufacturing network expansion and niche capabilities with overall CAPEX at 19% of sales

1Q FY27: Financial Summary - Highest Revenue, EBITDA and Profit momentum

1Q FY27 Financial Summary

[₹ Crore]	4Q FY26	1Q FY27	1Q FY26	Y-o-Y	Q-o-Q
Revenue	**1,812**	**2,026**	**1,570**	***29%***	***12%***
Gross Margins	*61.4%*	*62.7%*	*59.4%*	*+3.3%*	*+1.3%*
EBITDA	**523**	**644**	**389**	***66%***	***23%***
% to Revenue	*28.9%*	*31.8%*	*24.8%*	*+7.0%*	*+2.9%*
Net Profit	**279**	**368**	**163**	***+126%***	***+32%***
% to Revenue	*15.4%*	*18.2%*	*10.4%*	*+7.8%*	*+2.8%*
EPS (₹)	**5.2**	**6.8**	**3.0**	***+127%***	***+31%***

Comments

- Revenue : ₹ 2,026 Cr, increased 29% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF)
- Gross Margins : 62.7%, increased by 330 bps on better divisional mix
- R & D spends reported at ₹ 118 Cr* (5.8% of Revenue), increased by 74% due to development efforts toward building Advanced Biologics infrastructure
- EBITDA : ₹ 644 Cr, increased by 66% Y/Y
- EBITDA Margins : 31.8%, increased 700 bps Y/Y, due to favorable product mix and improving operational leverage
- Net Profit : ₹ 368 Cr, increased 126% Y/Y

* Including Capex R&D spends of ₹ 35 Cr towards Advanced Biologics (Gene therapy and ADC)

LAURUS Labs
Chemistry for Better Living

Additional Information

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions. The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its "Smart and Green" chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a "BBB" MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices. Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle "Chemistry for Better Living," Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

Investor relations

Vivek Kumar

T: +914066594366
E: investorrelations@lauruslabs.com
E: vivek.k@lauruslabs.com

For more information
Please visit our website www.lauruslabs.com

LAURUS Labs
Chemistry for Better Living

Please consider the environment before printing this Presentation